Hypoxia is a common feature of solid tumors that occurs across a wide variety of malignancies. Hypoxia and anemia (which contributes to tumor hypoxia) can lead to ionizing radiation and chemotherapy resistance by depriving tumor cells of the oxygen essential for the cytotoxic activities of these agents. Hypoxia may also reduce tumor sensitivity to radiation therapy and chemotherapy through one or more indirect mechanisms that include proteomic and genomic changes. These effects, in turn, can lead to increased invasiveness and metastatic potential, loss of apoptosis, and chaotic angiogenesis, thereby further increasing treatment resistance. Investigations of the prognostic significance of pretreatment tumor oxygenation status have shown that hypoxia (oxygen tension [pO 2 ] value ≤10 mmHg) is associated with lower overall and disease-free survival, greater recurrence, and less locoregional control in head and neck carcinoma, cervical carcinoma, and softtissue sarcoma. In view of the deleterious effect of hypoxia on standard cancer treatment, a variety of hypoxia-and anemia-targeted therapies have been studied in an effort to improve therapeutic effectiveness and patient outcomes. Early evidence from experimental and clinical studies suggests the administration of recombinant human erythropoietin (rHuEPO) may enhance the effectiveness of radiation therapy and chemotherapy by increasing hemoglobin levels and ameliorating anemia in patients with disease-or treatment-related anemia. However, further research is needed in the area of hypoxia-related treatment resistance and its reversal. The Oncologist 2004;9(suppl 5):31-40 The Oncologist 2004;9(suppl 5):31-40 www.TheOncologist.com
INTRODUCTION
Hypoxia is a characteristic pathophysiologic property of solid tumors that occurs across a wide range of experimental and human malignancies [1] . Hypoxic regions, defined as areas with oxygen tension (pO 2 ) values of 10 mmHg or lower, have been identified in locally advanced breast [1] and cervical [2] tumors and have been found to have a prevalence of approximately 60% in both tumor types investigated. Hypoxic regions have also been identified in head and neck cancer [3] [4] [5] [6] , rectal cancer [7, 8] , prostate cancer [9, 10] , pancreatic cancer [11] , brain tumors [12, 13] , soft-tissue sarcomas [14, 15] , and malignant melanoma [16] .
A growing body of evidence suggests that tumor hypoxia, acting through direct or indirect mechanisms, or both ( Fig. 1) , may contribute to resistance to standard radiation therapy, some chemotherapy, and chemoradiation, and subsequently, to poorer clinical outcome [1, 17] . Hypoxia may directly induce tumor resistance to radiation therapy and certain chemotherapeutic agents via deprivation of molecular oxygen, because such therapies require adequate intratumoral oxygen to be maximally cytotoxic. Indirectly, hypoxia may lead to treatment resistance by modulating (stimulating or inhibiting) gene expression and posttranscriptional or posttranslational effects, resulting in changes of the proteome that subsequently lead to alterations of proliferation kinetics, cell-cycle position, or numbers of cells remaining in the G 0 phase, thereby influencing the number of cells destroyed by radiation therapy or chemotherapy [1, 17, 18] . Hypoxia-induced proteomic changes may also lead to changes in cellular metabolism (e.g., induction of the glycolytic pathway); increased enzyme activities; elevated intracellular concentrations of glutathione and associated thiols that can compete with the target DNA; and increased transcription of glucose transporters (e.g., glucose transporter 1 [GLUT-1], GLUT-3), DNA repair enzymes, growth factors (e.g., transforming growth factor beta [TGF-β]); and proteins involved in cell detachment, invasiveness, and resistance. Many hypoxia-inducible genes are controlled by the transcription factor hypoxia-inducible factor 1 (HIF-1), including those involved in erythropoiesis, angiogenesis, glycolytic metabolism, and tumor invasiveness.
In addition to proteomic changes, hypoxia may promote genomic instability and change, thereby increasing genetic diversity; further, hypoxia may exert strong selective pressure. Hypoxia has been found to create selection pressure against wild-type p53 in tumors by promoting apoptosis of such cells. This allows for the emergence of a dominant resistant cell population with mutant p53, since such cells would be resistant to apoptosis [2, [19] [20] [21] [22] .
TUMOR HYPOXIA AND MECHANISMS OF RESISTANCE TO RADIATION THERAPY
Radiation therapy is an integral component of standard care for most locally advanced solid tumors, with chemotherapeutic agents generally administered concurrently for enhanced local tumor control [23, 24] . However, local recurrence may occur after radiation therapy, which portends a poor likelihood of long-term survival. While the primary factors leading to radioresistance and subsequent disease recurrence remain unclear [25] , one factor currently believed to play an important role in determining the outcome of curative-intent radiation therapy is intratumoral hypoxia. As shown in Figure 2 , radiosensitivity rapidly declines when 32 Hypoxia and Cancer Treatment Response [25] . The presence of oxygen may increase DNA damage via formation of oxygenderived free hydroxyl radicals, which occurs primarily after the interaction of radiation with intracellular water [26] . Alternatively, the presence of oxygen can stabilize ("fix") the highly reactive hydroxyl radicals that cause DNA damage, thus reducing the ability of the tumor cells to repair the damaged DNA strands [27, 28] . Because of this oxygenenhancement effect, the dose of single-fraction ionizing radiation required to achieve the same cell survival fraction is about two to three times higher under hypoxic conditions than under normoxic conditions; in other words, radiation therapy is about two to three times less effective in destroying hypoxic cells than normoxic cells [28] . Further, experimental studies have shown that surviving cells can re-establish tumors at the site of the original malignancy or in other areas following their transplantation [18] . The situation with fractionated radiotherapy is more complex, given the reoxygenation of the cells that occurs between treatments. With reoxygenation, the hypoxic tumor cells reacquire the radiosensitivity displayed by well-oxygenated cells, thereby increasing the responsiveness of the tumor to subsequent radiation therapy. However, the patterns of reoxygenation of the tumor cells are variable, and it is possible that some tumor cells reoxygenate less rapidly and extensively. These cells are, therefore, still relatively protected from radiation, continue to proliferate, and thereby limit the curability of the cancer by radiation therapy [18] . As indicated in Figure 1 and Table 1 , hypoxia may also substantially enhance radioresistance by inducing proteomic and genomic changes that lead to increases in the number of tumor cells with diminished apoptotic potential or increased proliferative and metastatic potential, or that lead to increases in the levels of repair enzymes or heat shock proteins [29] . Heat shock proteins, for example, HSP70 and HSP27, function mainly as molecular chaperones, allowing cells to adapt to changes in the environment and survive otherwise lethal conditions [30] . HSP70 is highly expressed in malignant tumor cells of various origins, including human breast tumors, whereas in normal cells, its expression is induced mainly by stress [31] . In a study reported in 2000, Nylandsted et al. demonstrated that inhibition of HSP70 synthesis resulted in massive death of human breast cancer cells [31] . Among other actions, HSP70 inhibits apoptosis induced by a wide range of stimuli, notably via inhibition of a signaling pathway independent of the classical caspase cascade [32] . Expression of HSP70 has additionally been associated with increased cell proliferation, poor differentiation, lymph node metastases, and poor therapeutic outcome in human breast cancer [33] [34] [35] [36] .
The prognostic significance of low pretreatment pO 2 values for responsiveness of tumors to radiation therapy has been the subject of numerous clinical studies. Gatenby et al., who used polarographic electrodes to measure oxygenation in lymph-node metastases of head and neck cancer, appear to be the first group to have reported substantial differences in pO 2 values in the tumors of patients who responded to radiation therapy, compared with tumors of nonresponders [29, 37] . With the introduction in 1989 of a computerized pO 2 histography system, prospective clinical trials were initiated to investigate the relationship between tumor oxygenation and radiation response in various forms of cancer; results of several of these trials are summarized below.
Hypoxia and Radiation Therapy Resistance in Head and Neck Cancer
In a study in patients with advanced squamous cell carcinoma of the head and neck treated with radiation therapy, Nordsmark et al. found a lower rate of actuarial 2-year tumor control in patients with pretreatment median hypoxic fractions (defined as % pO 2 values <2.5 mmHg) that were >15% versus those that were ≤15% (33% and 77%, respectively; p = 0.01) [3, 25] . Also, those patients who experienced locoregional failure had higher median hypoxic fractions than did patients who achieved locoregional tumor control (22% versus 6%) [3] . Brizel et al., in a study that compared radiation therapy outcomes in head and neck cancer patients with well-oxygenated versus poorly oxygenated primary tumors and metastatic lymph nodes, found that tumor hypoxia (median pO 2 <10 mmHg) adversely affected 2-year locoregional control (30% versus 73%, p = 0.01), disease-free survival rate (26% versus 73%, p = 0.005), and overall survival rate (35% versus 83%, p = 0.02) [38] . Additionally, the investigators observed that nodes that were poorly oxygenated prior to treatment were more likely to contain viable residual disease at postradiation neck dissection. Rudat et al., in a more recent study, evaluated the repeatability and prognostic impact of pretreatment pO 2 histography on survival in patients with advanced head and neck cancer treated with accelerated hyperfractionated radiation therapy with or without chemotherapy. Multivariate analysis showed the fraction of pO 2 values ≤2.5 mmHg to be the only significant (p = 0.05) prognostic factor for survival after fractionated radiation therapy [39] .
Hypoxia and Radiation Therapy Resistance in Cervical Cancer
Several studies have demonstrated that the pretreatment oxygenation status of tumors can predict overall survival, disease-free survival, and/or local tumor control in patients with cervical cancer [40] [41] [42] [43] [44] [45] . In 1993, Höckel et al. reported preliminary data from a study of the clinical relevance of pO 2 in patients undergoing radiation or surgery for advanced cancer of the uterine cervix [29, 40, 41] . Results of that 19-month (median) interim analysis indicated that a pO 2 level ≤10 mmHg discriminated between hypoxic and nonhypoxic cervical cancers. Specifically, patients with median pO 2 values >10 mmHg had significantly (p ≤ 0.002) higher rates of recurrence-free and overall survival than patients with lower pO 2 values. Results obtained after a 28-month followup showed that patients in the surgical subgroup who had hypoxic tumors had significantly (p = 0.036) larger tumor extensions and significantly (p = 0.026) more frequent (occult) parametrial spread as well as more pronounced lymphovascular space involvement (p = 0.036) than patients who had nonhypoxic tumors [46, 47] . Further, patients with hypoxic tumors had significantly lower 5-year disease-free (p = 0.009) and overall survival (p = 0.004) probabilities than their nonhypoxic counterparts, irrespective of the type of primary therapy administered (Fig. 3A-3C and Fig. 4) . Results of both univariate and multivariate analyses indicated that tumor oxygenation, expressed as median pO 2 , was the strongest independent predictor of overall (p = 0.006 and p = 0.004, respectively) and disease-free survival (p = 0.011 and p = 0.008, respectively) [46] . Knocke et al., in a study of patients with carcinoma of the uterine cervix treated with primary radiation therapy, found a 3-year disease-free survival rate of 69% for patients with pretreatment median pO 2 values >10 mmHg versus 34% for patients with median pO 2 values ≤10 mmHg (p < 0.02); corresponding values for local control were 47% and 84% (p = 0.05). Further, 70% of the patients who developed recurrent disease had median pO 2 values <10 mmHg [25, 44] . Strauss et al., who also examined median pO 2 in cervical cancer patients undergoing radiation therapy, found that a baseline pO 2 <10 mmHg was an adverse prognostic factor for local control, but only in patients who experienced sustained hypoxia after a 2-week course of radiation. Local control at 1 year was 42% in that subgroup and lower than that observed in patients who had normoxic tumors at baseline (68%) or who experienced reoxygenation of hypoxic tumors at 2 weeks (83%) [48] . Sundfor et al. evaluated tumor hypoxia and vascular density as predictors of metastasis in squamous cell carcinomas of the uterine cervix [43] . Those investigators found that a high incidence of metastasis was associated with poor oxygenation of the primary tumor but not with high vascular density. In a subsequent study, Sundfor et al. demonstrated that the hypoxic subvolume of the tumor, that is, the tumor volume having pO 2 values <5 mmHg, was a significant prognostic factor for locoregional control, disease-free survival, and overall survival [45] .
Hypoxia and Radiation Therapy Resistance in Other Cancers
Results similar to those observed in patients with head and neck and cervical cancers have also been found in patients with soft-tissue sarcomas [14, 15] . Brizel et al., in a study in this population, found a significantly lower 18-month actuarial disease-free survival rate for patients with median tumor pO 2 values <10 mmHg than for patients with median tumor pO 2 values >10 mmHg (35% versus 70%, p = 0.01) [14] . Interestingly, the median pO 2 for metastasizing tumors was significantly lower than that for nonmetastasizing tumors (7.5 mmHg versus 20 mmHg, p = 0.03). Nordsmark et al., in a study that explored the relationship between tumor oxygenation and cell proliferation in soft-tissue sarcomas, found a significant (p = 0.04) correlation between the median pO 2 and tumor cell potential doubling time, with the most rapidly proliferating tumor cells found in the most poorly oxygenated sarcomas. However, no correlation was detected between the level of hypoxia expressed by the percentage of pO 2 values ≤2.5 or ≤5.0 mmHg and tumor cell potential doubling time [15] .
Harrison et al. recently summarized the results of a series of studies (including several of those mentioned above) that demonstrate the adverse prognostic influence of a low pretreatment median pO 2 value or a high pretreatment median hypoxic fraction on outcome in patients undergoing radiation therapy, radiation/surgery, or chemoradiation [25] . As indicated by those authors, further research is needed to clarify whether hypoxia is solely predictive of response to radiation therapy or whether it has prognostic value independent of therapy, possibly reflecting other hypoxia-related mechanisms, including promotion of tumor progression.
TUMOR HYPOXIA AND RESISTANCE TO CHEMOTHERAPY
As is the case with radiation therapy, the efficacy of some chemotherapeutic agents can be decreased by a variety of direct and indirect mechanisms (Table 2) [17, 18] . Poor and fluctuating blood flow (which leads to acute hypoxia) as well as increased diffusion distances (which lead to chronic hypoxia) can result in the diminished and erratic distribution of chemotherapeutic agents, with a consequent effect on their therapeutic efficacy [17, 49] . Also, some chemotherapeutic agents, for example, cyclophosphamide, carboplatin are reduced generation of free radicals, thus limiting DNA damage by such agents as bleomycin (Blenoxane ® ; BristolMyers Squibb; Princeton, NJ) and anthracyclines; increased production of nucleophilic substances such as glutathione, which can compete with the target DNA for alkylation (as reflected in the acquired resistance to alkylating agents); and increased activity of DNA repair enzymes (affecting the efficacy of alkylating agents and platinum compounds) [17] . Also, hypoxia-induced changes in the expression of genes coding for oxygen-regulated proteins may result in inhibition of cell proliferation and increases in invasiveness, angiogenic potential, and drug resistance, and may thus impair treatment with chemotherapeutic agents [22] . Further, hypoxic stress proteins and loss of apoptotic potential can induce resistance to certain chemotherapeutic agents [19, 53, 54] .
MECHANISMS FOR BENEFICIAL EFFECTS OF RHUEPO ON RADIATION THERAPY AND CHEMOTHERAPY
Anemia is a common condition in cancer patients that may be caused by cancer treatment (radiation therapy or chemotherapy) or by the disease itself. Clinical trials have shown that the presence of anemia can have an adverse impact on both radiation therapy and chemotherapy outcomes, including survival [55] . An apparent relationship between anemia and increased hypoxia in solid tumors has also been shown [41, [56] [57] [58] [59] , although this relationship and its clinical relevance remain controversial [25, [60] [61] [62] . Nevertheless, emerging evidence suggests that the correction of anemia may enhance the radiosensitivity and chemosensitivity of solid tumors, supporting the proposed relationship between lower hemoglobin levels and greater hypoxia [63] [64] [65] [66] . One possible explanation for this enhancement effect is that early correction of anemia has the potential to modify the hypoxic environment of solid tumors. Degner and Sutherland, using a mathematical model of oxygen supply and oxygenation of tumor tissue, showed that increasing the hemoglobin level by 20% could produce a theoretical decrease in hypoxic tissue volume of approximately 30% [67] . Thus, correction of anemia may be a valuable strategy for oncologists to improve therapeutic and patient outcomes. Vaupel et al. have shown that the optimal hemoglobin level with regard to oxygenation status of gynecologic tumors is between 12 g/dl and 14 g/dl [59] . Another report has shown that even mild anemia may be a major causative factor for the development of hypoxia or anoxia in breast tumors [58] . In that study, the investigators developed a novel measurement, called the oxygenation gain factor (OGF), that characterized the relationship between oxygenation status and rising hemoglobin level. Using the OGF, they demonstrated that the oxygenation status of primary breast cancers depends critically on hemoglobin level. Median hemoglobin in the range of 8.5 to 14.7 g/dl correlated with exponentially greater median pO 2 values (3-15 mmHg) in breast tumors. Median pO 2 values in normal tissue are much higher (e.g., 51 mmHg in subcutis and 37 mmHg in skeletal muscle) and remain relatively constant over hemoglobin levels of 10-16 g/dl.
CORRECTING ANEMIA
One approach to correcting anemia in cancer patients is administration of recombinant human erythropoietin (rHuEPO, epoetin alfa), which elevates hemoglobin levels and 36 Hypoxia and Cancer Treatment Response Table 2 . Selected mechanisms for hypoxia-related tumor resistance to chemotherapy [6, 17, 18, 59] 
Direct effects
• Decreased generation of free radicals, and thus, less DNA damage (bleomycin, anthracyclines)
Indirect effects related to proteomic changes
• Slowing of proliferation kinetics; increase in number of cells in G 0 phase
• G 1 /S-phase arrest (e.g., vinca alkaloids, methotrexate)
• Elevated levels of glutathione and DNA-repair enzymes (alkylating agents, bleomycin, platinum compounds)
Indirect effects related to genomic changes and clonal selection
• Loss of apoptosis and differentiation hematocrit. Several experimental and clinical studies have examined the impact of rHuEPO treatment on radiosensitivity and chemosensitivity. In a study using a tumor-associated and carboplatin-induced anemia model in rats, prevention of anemia with rHuEPO treatment resulted in a significant increase in tumor radiosensitivity, almost to the level found in nonanemic animals (Fig. 5) [68, 69] . In a similar study using a carboplatin-induced anemia model, delay in tumor regrowth after administration of cyclophosphamide was significantly shorter in the anemic group (8.6 days) than in the nonanemic control group or the group treated with rHuEPO (13.3 days) (Fig. 6) [66] . These results were interpreted as suggesting that chemotherapy-induced anemia reduces the cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia with rHuEPO increases sensitivity to this agent, probably as a result of an improved oxygen supply to the tumor tissue. Silver and Piver, in a study in severe combined immunodeficient mice with engrafted human ovarian cancer, found a significantly (p < 0.05) greater improvement in tumor regression in the group treated with rHuEPO plus cisplatin, compared with the group treated with cisplatin only [65] . Again, the improved chemosensitivity was attributed to better oxygenation of the tumor, as a result of a higher hematocrit level. In a series of studies, Stüben et al. demonstrated that rHuEPO impacted radiosensitivity of experimental human tumors in mice [70] [71] [72] . In one study, tumor growth delay was significantly longer in animals that were protected from anemia by rHuEPO than in anemic animals [72] . Two additional studies demonstrated that anemia reduced the efficacy of radiotherapy and that rHuEPO administered to anemic mice restored radiosensitivity of experimental human tumors [70, 71] .
Limited clinical trial experience using rHuEPO to prevent or correct anemia has indicated improvement in locoregional tumor control following radiation therapy [73] [74] [75] or radiochemotherapy [76] ; however, extension of this research in the clinical setting is required.
CONCLUSION AND SUMMARY
Tumor hypoxia may directly contribute to the resistance of the cancer patient to radiation therapy or chemotherapy via deprivation of the oxygen essential for the cytotoxic actions of these agents. Indirectly, tumor hypoxia may contribute to radioresistance and chemoresistance by inducing proteomic and genomic changes that lead ultimately to malignant progression, with reduced local control and metastatic spread, and ultimately, increased resistance and decreased survival time. A direct association between hypoxia and anemia appears likely, and anemia is a modifiable condition in many cancer patients. This being the case, reducing tumor hypoxia by correcting anemia with rHuEPO appears to offer one possible therapeutic option for enhancing the effectiveness of standard cancer therapies. Ongoing clinical trials should help define the role of rHuEPO with respect to improvement of radiation therapy and chemotherapy. However, other strategies aimed at improving treatment sensitivity in hypoxic tumors will also have to be explored (e.g., brachytherapy, alternative radiation and chemotherapy schedules, and therapies specifically targeted at the hypoxic microenvironment) in an effort to assure optimal treatment of cancer patients. 
